FDA Approves First Once-Daily Single Inhaler Triple Therapy for COPD

Today's blog features the FDA announcement that fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) (Trelegy Ellipta, GlaxoSmithKline and Innoviva), has been approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). 

This single inhaler triple therapy is intended for patients with COPD who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction. To learn more on this new therapy, please click HERE!

Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to efficiently and effectively place, manage and oversee our self-funded client's pharmacy benefit management programs. The PPS platform provides turnkey solutions with proven market-leading PBM partners that offer, on average, 10-15% savings.